🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7 results for “Alfasigma S.p.A.” Clear

  1. GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets

    Alfasigma S.p.A.

    Ulcerative colitis

    phase 3 small molecule active

    1 trial

  2. GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets

    Alfasigma S.p.A.

    Juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  3. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets

    Alfasigma S.p.A.

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

  4. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets, Composition apart from the active substance otherwise to identical to IMP

    Alfasigma S.p.A.

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  5. Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets, GLPG0634

    Alfasigma S.p.A.

    Polyarticular-course juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  6. A TWO-PART ABSOLUTE BIOAVAILABILITY STUDY DESIGNED TO EVALUATE THE PHARMACOKINETIC PROFILE OF VELUSETRAG FOLLOWING SINGLE-DOSE ADMINISTRATION OF INTRAVENOUS AND ORAL CAPSULE FORMULATIONS IN HEALTHY MALE AND FEMALE SUBJECTS

    Alfasigma S.p.A.

    chronic intestinal pseudo-obstruction (CIPO)

    phase 1 other active

    1 trial

  7. GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets

    Alfasigma S.p.A.

    juvenile idiopathic arthritis

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources